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Triple Antithrombotic
Therapy With Prasugrel
in the Stented Patient
Concern for More Bleeding*
Paul A. Gurbel, MD, Udaya S. Tantry, PHD
altimore, Maryland
There is a large body of evidence, including results of
prospective trials, that supports oral anticoagulation therapy
(OAT) as the optimal strategy to prevent fibrin-centric
thrombotic events (FCTEs). Examples of FCTEs include
thromboembolism in patients with mechanical heart valves,
deep vein thrombosis, and atrial fibrillation (AF) (1). In a
large prospective trial, warfarin was found to be superior to
dual antiplatelet therapy (DAPT) with aspirin  clopi-
ogrel in the prevention of vascular events in patients with
F plus 1 or more risk factors for stroke (2). European and
merican guidelines include a Class I recommendation for
ifelong OAT in patients with AF who are at moderate to
igh risk of thromboembolism (3). It has also been dem-
nstrated in prospective, randomized trials that DAPT with
spirin and a thienopyridine is superior to aspirin  warfa-
in in the prevention of the platelet-centric thrombotic
vent (PCTE), stent thrombosis (4). In the European and
merican Guidelines there is a Class I recommendation to
dminister uninterrupted DAPT for 1 to 12 months de-
ending on the type of stent used (5,6).
See page 2060
However, in everyday practice, things are not as cut and
dried. Cardiologists regularly encounter patients requiring
prophylaxis against both events. It is estimated that 5% of
atients undergoing stenting also meet the criteria for OAT
7). It is not surprising that there is a major concern for
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ith aspirin  clopidogrel  warfarin than DAPT (7).
lthough TAT is currently recommended for the patient at
oderate to high risk of an FCTE undergoing stenting,
here are no large-scale prospective data addressing how to
est deal with this important clinical conundrum, and the
vailable evidence base to address the efficacy and safety of
AT is limited (5–7). Despite the limited information,
pecific recommendations based on stent type, clinical
etting (acute coronary syndrome [ACS] vs. elective), and
emorrhagic risk have even been given (7). The best
rospective evidence of excessive (and unacceptable) bleed-
ng from TAT comes from trials of ACS patients treated
ith DAPT  a new oral anticoagulant. For example, the
ddition of apixaban, a factor Xa inhibitor, at a dose shown
o be more effective than warfarin in stroke prophylaxis in
F, to aspirin  clopidogrel, was associated with excessive
leeding that resulted in the premature termination of a
ajor ACS trial (8). Greater bleeding was also observed
ith AF-effective doses of dabigatran in addition to aspirin 
lopidogrel versus aspirin  clopidogrel (9). In a recently
eported prospective trial, both Thrombolysis In Myocardial
nfarction (TIMI) bleeding and all-cause mortality were
60% higher in stented patients treated with TAT with
lopidogrel versus clopidogrel  warfarin (10).
Where else is the evidence not so cut and dried? Con-
roversy exists in the area of personalized antiplatelet ther-
py. Despite the overwhelming evidence of a slow, weak,
nd unpredictable pharmacodynamic effect, clopidogrel re-
ains the most widely used P2Y12 inhibitor in the patient
ndergoing stenting. Moreover, a substantial proportion of
lopidogrel-treated patients have on-treatment high platelet
eactivity (HPR) to adenosine diphosphate. Based on a large
ody of observational evidence, HPR has been identified as
risk factor for post-percutaneous coronary intervention
schemic event occurrence, including stent thrombosis (11).
owever, the relationship of HPR to ischemic risk has
ever been studied in patients on TAT. Furthermore, 3
rospective trials of personalized antiplatelet therapy failed
o demonstrate the utility of adjusting P2Y12 inhibitor
therapy based on platelet function testing. In addition, the
safety and efficacy of the new P2Y12 inhibitors have never
been assessed in combination with OAT (12–14). In the
TRITONTIMI 38 (Trial to Assess Improvement in
Therapeutic Outcomes by Optimizing Platelet Inhibition
with Prasugrel–Thrombolysis in Myocardial Infarction 38)
study, patients were excluded from enrollment if they were
receiving OAT that could not be safely discontinued. If
OAT was indicated, a blinded study drug was discontin-
ued, and open-label thienopyridine use was left to the
discretion of the treating physician (15). Finally, in the
boxed warning addressing “bleeding risk” contained in
the prescribing information for prasugrel, caution was
given regarding the concomitant use of medications that
increase the risk of bleeding (e.g., warfarin) (16).
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Triple Antithrombotic Therapy May 21, 2013:2067–9In this issue of the Journal, Sarafoff et al. (17) report their
xperience in 377 consecutive patients who underwent
uccessful stenting and platelet function testing and were
ischarged with a 6-month regimen of TAT. Among these
atients, 21 were treated with prasugrel instead of clopi-
ogrel. HPR determined by impedance aggregometry was
he indication for prasugrel in the majority (86%). The
ndication for OAT in the clopidogrel group was largely
trial fibrillation (80%), whereas the indication in the
rasugrel group was left ventricular thrombus (33%), atrial
brillation (29%), and pulmonary embolism/deep vein
hrombosis (19%). Even though the study was not powered
o assess clinical endpoints, prasugrel therapy was associated
ith a disturbing nearly 5-fold greater TIMI major bleeding
han clopidogrel therapy. The information on where the
leeding occurred is limited except that 1 intracranial
emorrhage was reported in the prasugrel group. Despite
he lower on-treatment platelet reactivity in the prasugrel
roup, no significant difference in the combined ischemic
ndpoint occurrence was observed (17). The variable and
reater on-clopidogrel platelet reactivity observed by the
uthors is consistent with previous reports from the same
roup, and the successful effect of prasugrel in overcoming
PR is similar to that reported by others (18,19). The
urrent study supports the data obtained in the absence of
AT from the TRITON trial that demonstrated greater
leeding with prasugrel compared with clopidogrel (15). In
he current study, the coadministration of OAT with
rasugrel appeared to exaggerate this difference.
The authors should be recognized for their exploration
nto the uncharted territory of TAT with prasugrel. The
rimary indication for prasugrel use in their study was HPR
n clopidogrel therapy. However, at this time, we do not
ave large-scale prospective data demonstrating that per-
onalizing antiplatelet therapy is effective and safe in stented
atients whether or not they are receiving OAT. Prelimi-
ary data from the same authors and others suggest that
here may be a therapeutic window for P2Y12 inhibitors in
tented patients not receiving OAT (11,18). Further work
hould be done to explore this concept in those receiving
AT. Two scenarios are possible: 1) The therapeutic window
f platelet reactivity may not be the same in the presence of
AT. Bleeding risk may be reduced by avoiding overinhibi-
ion and titrating the P2Y12 inhibitor into the upper therapeu-
tic range of on-treatment platelet reactivity. In the current
study, low on-treatment platelet reactivity in the prasugrel-
treated patients may have contributed to the observed
excessive bleeding. 2) The intensity of anticoagulant effect
needed for optimal prevention of FCTEmay be lower in the
presence of P2Y12 inhibition.
We know that the P2Y12 receptor plays a central role in
ost–stent thrombotic event occurrence, and its inhibition
annot be substituted by anticoagulation (4). Similarly, in
atients at moderate to high risk of FCTE occurrence,
2Y12 inhibition cannot substitute for OAT (4). Balancingthe intensity of the 2 therapies is a delicate act. In the future,the balancing act may be facilitated by a laboratory method
that can assess both coagulation and platelet reactivity in
these bleeding- and thrombosis-prone patients. We agree
with the authors’ conclusion that a substantial amount of
work is necessary before we coadminister OAT with a
potent P2Y12 inhibitor such as prasugrel.
Reprint requests and correspondence: Dr. Paul A. Gurbel, Sinai
Center for Thrombosis Research, Sinai Hospital of Baltimore,
2401 West Belvedere Avenue, Baltimore, Maryland 21215.
E-mail: pgurbel@lifebridgehealth.org.
REFERENCES
1. Guyatt GH, Akl EA, Crowther M, et al. American College of
Chest Physicians Antithrombotic Therapy and Prevention of
Thrombosis Panel. Executive summary: Antithrombotic Therapy
and Prevention of Thrombosis, 9th ed: American College of Chest
Physicians Evidence-Based Clinical Practice Guidelines. Chest
2012;141:7S–47S.
2. Connolly SJ, Pogue J, Hart RG, et al., ACTIVE Investigators, Effect
of clopidogrel added to aspirin in patients with atrial fibrillation.
N Engl J Med 2009;360:2066–78.
3. ACC/AHA/ESC 2006 guidelines for the management of patients
with atrial fibrillation–executive summary: a report of the American
College of Cardiology/American Heart Association Task Force on
Practice Guidelines and the European Society of Cardiology Com-
mittee for Practice Guidelines (Writing Committee to Revise the 2001
Guidelines for the Management of Patients With Atrial Fibrillation).
J Am Coll Cardiol 2006;48:854–906.
4. Rubboli A, Milandri M, Castelvetri C, Cosmi B. Meta-analysis of
trials comparing oral anticoagulation and aspirin versus dual antiplate-
let therapy after coronary stenting. Clues for the management of
patients with an indication for long-term anticoagulation undergoing
coronary stenting. Cardiology 2005;104:101–6.
5. Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/
SCAI guideline for percutaneous coronary intervention. A report of
the American College of Cardiology Foundation/American Heart
Association Task Force on Practice Guidelines and the Society for
Cardiovascular Angiography and Interventions. J Am Coll Cardiol
2011;58:e44–122.
6. Wijns W, Kolh P, Danchin N, et al. Guidelines on myocardial
revascularization. Eur Heart J 2010;31:2501–55.
7. Lip GY, Huber K, Andreotti F, et al. Consensus Document of
European Society of Cardiology Working Group on Thrombosis.
Antithrombotic management of atrial fibrillation patients presenting
with acute coronary syndrome and/or undergoing coronary stenting.
Eur Heart J 2010;31:1311–8.
8. Alexander JH, Lopes RD, James S, et al., APPRAISE-2 Investigators.
Apixaban with antiplatelet therapy after acute coronary syndrome.
N Engl J Med 2011;365:699–708.
9. Oldgren J, Budaj A, Granger CB, et al., RE-DEEM Investigators.
Dabigatran vs. placebo in patients with acute coronary syndromes on
dual antiplatelet therapy: a randomized, double-blind, phase II trial.
Eur Heart J 2011;32:2781–9.
10. Dewilde W, Oirbans T, Verheugt F, et al. The WOEST trial: first
randomized trial comparing two regimens with and without aspirin in
patients on oral anticoagulant therapy undergoing coronary stenting.
Paper presented at European Society of Cardiology, Hotline III;
Munich; August 28, 2012.
11. Gurbel PA, Tantry US. Do platelet function testing and genotyping
improve outcome in patients treated with antithrombotic agents?:
Platelet function testing and genotyping improve outcome in patients
treated with antithrombotic agents. Circulation 2012;125:1276–87.
12. Price MJ, Berger PB, Teirstein PS, et al., GRAVITAS Investigators.
Standard- vs high-dose clopidogrel based on platelet function testing
after percutaneous coronary intervention: the GRAVITAS random-
ized trial. JAMA 2011;305:1097–105.
13. Trenk D, Stone GW, Gawaz M, et al. A randomized trial of prasugrel
versus clopidogrel in patients with high platelet reactivity on clopi-
11
1
1
1
1
2069JACC Vol. 61, No. 20, 2013 Gurbel and Tantry
May 21, 2013:2067–9 Triple Antithrombotic Therapydogrel after elective percutaneous coronary intervention with
implantation of drug-eluting stents: results of the TRIGGER-PCI
(Testing Platelet Reactivity In Patients Undergoing Elective Stent
Placement on Clopidogrel to Guide Alternative Therapy With
Prasugrel) study. J Am Coll Cardiol 2012;59:2159–64.
4. Collet JP, Cuisset T, Rangé G, et al., ARCTIC Investigators. Bedside
monitoring to adjust antiplatelet therapy for coronary stenting. N Engl
J Med 2012;367:2100–9.
5. Wiviott SD, Braunwald E, McCabe CH, et al., TRITON-TIMI 38
Investigators. Prasugrel versus clopidogrel in patients with acute
coronary syndromes. N Engl J Med 2007;357:2001–15.
6. EFFIENT (prasugrel) tablets prescribing information. Available at:
http://pi.lilly.com/us/effient.pdf. Accessed on January 29, 2013.7. Sarafoff N, Martischnig A, Wealer J, et al. Triple therapy with aspirin,
prasugrel, and vitamin K antagonists in patients with drug-elutingstent implantation and an indication for oral anticoagulation. J Am
Coll Cardiol 2013;61:2060–6.
8. Sibbing D, Steinhubl SR, Schulz S, et al. Platelet aggregation and its
association with stent thrombosis and bleeding in clopidogrel-treated
patients: initial evidence of a therapeutic window. J Am Coll Cardiol
2010;56:317–8.
9. Alexopoulos D, Dimitropoulos G, Davlouros P, et al. Prasugrel
overcomes high on-clopidogrel platelet reactivity post-stenting more
effectively than high-dose (150-mg) clopidogrel: the importance of
CYP2C19*2 genotyping. J Am Coll Cardiol Intv 2011;4:403–10.Key Words: clopidogrel y drug-eluting stent y high platelet reactivity
y prasugrel y vitamin K antagonist.
